John Mascarenhas
Icahn School of Medicine at Mount Sinai · Mt. Sinai · MOUNT SINAI HOSPITAL
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
19
all conditions, ClinicalTrials.gov
NIH grants tied to them
2
NIH RePORTER
Trial papers
73
PubMed author-name match
Trials
Studies that name John Mascarenhas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07872709 · Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative NeoplasmsJohn Mascarenhas · not yet recruiting · Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN · study director
- Ph1/Ph2NCT07734077 · Revumenib in Patients With MyelofibrosisJohn Mascarenhas · not yet recruiting · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · study chair
- Ph2NCT07447817 · Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasJohn Mascarenhas · recruiting · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · study chair
- Ph1NCT07320235 · Imetelstat Combinations in Relapsed AMLDouglas Tremblay · recruiting · Relapsed Acute Myeloid Leukemia · study chair
- Ph2NCT06541249 · MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai · recruiting · Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF) · study chair
- Ph1NCT06343805 · A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · recruiting · Primary Myelofibrosis · principal investigator
- Ph2NCT05467800 · Study of Canakinumab in Patients With MyelofibrosisJohn Mascarenhas · active not recruiting · Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF · study chair
- Ph2NCT04281498 · Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationJohn Mascarenhas · completed · Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation · study chair
- Ph1NCT03895112 · MPN-RC 118 AVID200 in MyelofibrosisJohn Mascarenhas · completed · Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis · study chair
- Ph2NCT03065400 · PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsJohn Mascarenhas · completed · Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · study chair
- Ph1NCT02407080 · Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential ThrombocythemiaJohn Mascarenhas · completed · Polycythemia Vera, Essential Thrombocythemia · study chair
- Ph1/Ph2NCT02076191 · Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AMLJohn Mascarenhas · completed · Myeloproliferative Neoplasms · study chair
- Ph2NCT01790295 · Ruxolitinib Prior to Transplant in Patients With MyelofibrosisJohn Mascarenhas · terminated · Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis · principal investigator
- Ph1/Ph2NCT01693601 · Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)John Mascarenhas · completed · Myelofibrosis · principal investigator
- Ph1NCT01291784 · Anti-TGF-beta Therapy in Patients With MyelofibrosisJohn Mascarenhas · terminated · Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · principal investigator
- Ph3NCT01259856 · Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)Ronald Hoffman · completed · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia · study chair
- Ph2NCT01259817 · Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)Ronald Hoffman · completed · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia · principal investigator
- N/ANCT00665067 · Correlative Biomarker Study in Patients With Myeloproliferative DisordersIcahn School of Medicine at Mount Sinai · completed · Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis · principal investigator
- Ph2NCT00572897 · Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for MyelofibrosisJohn Mascarenhas · completed · Myelofibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 4: MPN Clinical ConsortiumP01CA108671 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2018 to 2026 · $757,581 awarded in 2026Grant number is on one of their registry trials
- Prevalence of Chronic Hematopoiesis of Indeterminate Potential Among WTC RespondersU01OH012071 · NIOSH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2020 · $499,631 awarded in 2020Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:01 UTC. The ranking covers the 200 most relevant of 73 PubMed records, and a shared surname and initials can bring in a namesake. All 73 on PubMed
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.JAMA Oncol · 2018355 citationsRCR 11.4
- The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.JAMA Ophthalmol · 2013269 citationsRCR 12.9
- Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).Arch Ophthalmol · 2012165 citationsRCR 7.4
- 152 citationsRCR 6.2
- Comparison of natamycin and voriconazole for the treatment of fungal keratitis.Arch Ophthalmol · 2010141 citationsRCR 6.0
- 130 citationsRCR 11.7
- The clinical differentiation of bacterial and fungal keratitis: a photographic survey.Invest Ophthalmol Vis Sci · 2012121 citationsRCR 5.5
- 113 citationsRCR 3.4
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Biol Blood Marrow Transplant · 2016113 citationsRCR 4.4
- Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belém, Brazil.Bull World Health Organ · 1996105 citationsRCR 3.8